Metastatic Castrate Resistant Prostate Cancer (mCRPC)
mCRPC is advanced prostate cancer that progresses despite androgen deprivation. Genomic alterations can define eligibility for targeted therapies.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Metastatic Castrate Resistant Prostate Cancer (mCRPC) in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| BRCA1 and BRCA2 |
| |
| BRCA1, BRCA2 and ATM |
| |
| Homologous recombination repair (HRR) genes |
|
Defined at the solid tumor level and applicable to Metastatic Castrate Resistant Prostate Cancer (mCRPC) and other solid tumor cancers.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Metastatic Castrate Resistant Prostate Cancer (mCRPC). Select a therapy to view the specific approval and eligible tests.
BRCA1 and BRCA2 (alterations (including mutations))
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High)
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High); TMB (TMB ≥ 10 mutations per megabase)
BRCA1 and BRCA2 (alterations (including mutations)); BRCA1, BRCA2 and ATM (alterations (including mutations)); Homologous recombination repair (HRR) genes (BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L alterations)
BRCA1 and BRCA2 (alterations (including mutations))
RET (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)
BRCA1 and BRCA2 (alterations (including mutations))
NTRK1, NTRK2 and NTRK3 (fusions)